Onconetix, Inc. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
Onconetix, Inc. (ONCO) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 24.21 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2026-08-13
- Onconetix, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2026-03-31 was 1.14M shares, a 40995.41% increase year-over-year.
- Onconetix, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2025-03-31 was 2.77K shares, a 98.60% decline year-over-year.
- Onconetix, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2024-03-31 was 197.49K shares, a 96.25% decline year-over-year.
- Onconetix, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2023-09-30 was 7.90M shares.
- Onconetix, Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2025 was 6.40M shares, a 46199.81% increase from fiscal 2024.
- Onconetix, Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2024 was 13.83K shares, a 93.00% decline from fiscal 2023.
- Onconetix, Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2023 was 197.49K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 0 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 24.21M shares 10-Q · filed 2026-08-13 | ||||||||
| 2026-03-31 | 1.14M shares 10-Q · filed 2026-05-13 | ||||||||
| 2025-12-31 | 6.40M shares 10-K · filed 2026-03-13 | ||||||||
| 2025-09-30 | 4.38M shares 10-Q · filed 2025-11-13 | ||||||||
| 2025-06-30 | 276.00 shares 10-Q · filed 2026-08-13 | 13.82K shares 10-Q · filed 2025-08-14 | |||||||
| 2025-03-31 | 2.77K shares 10-Q · filed 2026-05-13 | 1.18M shares 10-Q · filed 2025-06-12 | |||||||
| 2024-12-31 | 13.83K shares 10-K · filed 2026-03-13 | 1.18M shares 10-K · filed 2025-06-02 | |||||||
| 2024-09-30 | 6.86K shares 10-Q · filed 2025-11-13 | 583.48K shares 10-Q · filed 2024-12-10 | |||||||
| 2024-06-30 | 2.32K shares 10-Q · filed 2025-08-14 | 7.90M shares 10-Q · filed 2024-08-29 | |||||||
| 2024-03-31 | 197.49K shares 10-Q · filed 2025-06-12 | 7.90M shares 10-Q · filed 2024-05-20 | |||||||
| 2023-12-31 | 197.49K shares 10-K · filed 2025-06-02 | ||||||||
| 2023-09-30 | 7.90M shares 10-Q · filed 2023-11-17 | 197.49K shares 10-Q · filed 2024-12-10 | 5.38M shares 10-Q · filed 2023-11-17 | ||||||
| 2023-06-30 | 5.26M shares 10-Q · filed 2024-08-29 | ||||||||
| 2023-03-31 | 5.26M shares 10-Q · filed 2024-05-20 | ||||||||
| 2022-10-04 | 491.64K shares 10-Q · filed 2022-11-14 | ||||||||
| 2022-06-30 | 1.36M shares 10-Q · filed 2023-10-20 | ||||||||
| 2022-03-31 | 111.11K shares 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |